アレルギー膠原病内科（リウマチ・膠原病内科）の紹介 研究業績 Achievements

アレルギー膠原病内科（リウマチ・膠原病内科）の研究活動の結果として、受賞、論文、学会発表、書籍、招待講演の一部をご紹介いたします。

原著- Original articles -

2019年

1. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.

   Hatemi G., Mahr A., Ishigatsubo Y., Song Y.W., Takeno M., Kim D., Melikoğlu M., Cheng S., McCue S, Paris M., Chen M., Yazici Y.
   N Engl J Med, 2019; 381 (20): 1918-1928

2. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

   Distler O., Kristin B Highland K.B., Martina Gahlemann M., Azuma A., Fischer A., Mayes M.D., Raghu G., Sauter W., Girard M., Alves M., Beaty E.C., Stowasser S., Tetzlaff K., Kuwana M., Maher T.M., SENSCIS Trial Investigators.
   N Engl J Med, 2019; 380(26): 2518-2528

2018年

1. Predictors for favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease.

   Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M.
   Circ J. 2018; 82(2): 546-554. doi: 10.1253/circj.CJ-17-0351

2. Anti-aminoacyl tRNA synthetase antibodies in Japanese patients with interstitial lung disease.

   Sato S, Hirakata M, Asano K, and Kuwana M.
   Open J. Rheumatol. Autoimmun. Dis. 2018; 8: 34-42. doi: org/10.4236/ojra.2018.81003.

3. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis:A case report.

   Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, and KawakamiA.
   Medicine (Baltimore). 2018; 97(15): e0436. doi: 10.1097/MD.0000000000010436.

4. Diagnostic criteria, severity classification, and guidelines of systemic sclerosis.

   Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, and Ihn H.
   J. Dermatol. 2018; 45(6): 633-691.　doi:10.1111/1346-8138.14162.

5. Personalized medicine in connective tissue disease: historical and future perspectives.

   Kuwana M.
   Pers. Med. Univers. 2018; 7(1): 1-6. doi: org/10.1016/j.pmu.2018.04.004.

6. Reccurence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.

   Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, and Kawakami A.
   Medicine (Baltimore). 2018; 97(26): e11024. doi: 10.1097/MD.0000000000011024.

7. Hughes–Stovin syndrome with pulmonary aneurysms and renal dysfunction mimicking polyarteritis nodosa.

   Watanabe E, Nishina K, Yabe H, Gono T, Terai C.
   Modern Rheumatol Case Rep. 2018; doi.org/10.1080/24725625.2017.1379168.

8. Progressive destructive bronchiolectasis followed by appearance of multiple pulmonary cystic lesions mimicking honeycombing in a patient with rheumatoid arthritis.

   Sugitani N, Gono T, Tokuda H, Takemura T, Moda M, Emoto N, Kiire-Kobayashi A, Kasai S, Okochi Y amd Tamanaka H.
   Modern Rheumatol Case Rep. 2018; doi.org/10.1080/24725625.2017.1391966.

9. Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).

   Oku K, Atsumi T, Akiyama Y, Amano H, AzumaN, BohgakiT, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, and Sumida T.
   Mod. Rheumatol. 2018; 28(4): 642-648. doi: 10.1080/14397595.2017.

10. Association of serum soluble CD163 with polymyositis and dermatomyositis, predominantly with anti-MDA5 antibody-positive cases.

    Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, and Yamanaka H.
    J. Rheumatol. 2018; 45(7): 947-955. doi: 10.3899/jrheum.170997.

11. KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease.

    Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, and Assassi S.
    J. Rheumatol. 2018; 54(8): 1153-1158. doi: 10.3899/jrheum.170518.

12. T cells from induced and spontaneous models of SLE recognize a common T cell epitope on β2-glycoprotein I.

    Salem D, Subang R, Kuwana M, Levine JS, and Rauch J.
    Cell. Mol. Immunol. doi.org/10.1038/s41423-018-0013-3. [Epub ahead of print]

13. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients.

    Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Ukichi T, Kaieda S, Naniwa T, Kuwana M, and A Multicentre Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) Investigators.
    Rheumatology (Oxford). doi: 10.1093/rheumatology/key060. [Epub ahead of print]

14. Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody.

    Gono T, Okazaki Y, Murakami A, Kuwana M.
    Mod Rheumatol. 2018 Mar 13:1-17. doi: 10.1080/14397595.2018.1452179.

15. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.

    Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, Yoshioka Y, Kobayashi K, Takase-Minegishi K, Watanabe T, Hamada N, Nagai H, Tsuchida N, Soejima Y, Nakano H, Kamiyama R, Uehara T, Kirino Y, Sekiguchi A, Ihata A, Ohno S, Nagaoka S, Nakajima H.
    Arthritis Res Ther. 2018 ;20(1):7.

16. Dysfunction of TRIM21 in interferon signature of systemic lupus erythematosus.

    Kamiyama R, Yoshimi R, Takeno M, Iribe Y, Tsukahara T, Kishimoto D, Kunishita Y, Sugiyama Y, Tsuchida N, Nakano H, Minegishi K, Tamura M, Asami Y, Kirino Y, Ishigatsubo Y, Ozato K, Nakajima H.
    Mod Rheumatol. 2018 in press

17. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.

    Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, and Ariga T.
    Mod. Rheumatol. doi: 10.1080/14397595.2018.1452353. [Epub ahead of print]

18. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify endotype to tocilizumab therapy.

    Shima Y, Kawaguchi Y, and Kuwana M.
    Mod. Rheumatol. doi: 10.1080/14397595.2018.1452178. [Epub ahead of print]

19. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week multicenter postmarketing surveillance study.

    Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Yamamoto K, Ikeuchi S, Kushimoto S, and Koike T.
    Mod. Rheumatol. doi: 10.1080/14397595.2018.1460230. [Epub ahead of print]

20. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor outcome in the chronic phase of interstitial lung disease in patients with dermatomyositis.

    Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, and Hoshino T.
    Respir. Invest. doi: 10.1016/j.resinv.2018.07.007. [Epub ahead of print]

21. Impact of the genetic variants of GLCCI1 on clinical features of asthmatic patients.

    Chiba S, Nakamura Y, Mizuno T, Abe K, Horii Y, Nagashima H, Sasaki N, Kanno H, Tanita T, Yamauchi K.
    Clin Respir J. 2018; 12:1166-73.

22. Changes in pulmonary function of residents in Sanriku Seacoast following the tsunami disaster from the Great East Japan Earthquake.

    Nagashima H, Fujimura I, Nakamura Y, Utsumi Y, Yamauchi K, Takikawa Y, Yokoyama Y, Sakata K, Kobayashi S, Ogawa A.
    Respir Investig. 2018;56:184-88.

23. Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients.

    Abe K, Nakamura Y, Yamauchi K, Maemondo M.
    Clin Mol Allergy. 2018;6:9

24. Rapidly progressive multiple digital gangrenes and diffuse alveolar damage in a patient with anti-synthetase antibody complicated with gastric cancer.

    Fukue R, Gono T, Hayashi H, Tarasaki Y, and Kuwana M.
    J. Clin. Rheumatol. In press.

25. A case of cancer-associated myositis with anti-Mi-2 antibodies: false-positive anti-transcriptional intermediary factor 1- antibodies by commercial enzyme-linked immunosorbent assay.

    Nawata T, Kubo M, Oishi K, Murata Y, Oishi M, Okazaki Y, Omoto M, Kanda T, Kuwana M, and Yano M.
    Int. J. Rheum. Dis. In press.

26. Dysregulated heme oxygenase-1-low M2-like macrophages augment lupus nephritis via Bach1 induced by type-I interferons.

    Kishimoto D, Kirino Y, Tamura M, Takeno M, Kunishita Y, Takase-Minegishi K, Nakano H, Kato I, Nagahama K, Yoshimi R, Igarashi K, Aoki I, Nakajima H.
    Arthritis Research & Therapy 2018, in press

27. Measurement of daily sodium excretion in patients with chronic kidney disease; special reference to the difference between the amount measured from 24 h collected urine sample and the estimated amount from a spot urine.

    Amano H, Kobayashi S, Terawaki H, Ogura M, Kawaguchi Y, Yokoo T.
    Ren Fail. 2018; 40(1): 238-242.doi: 10.1080/0886022X.2018.1456452.

2017年

1. Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) Syndrome with Significant Bilateral Pleural Effusions.

   Hasegawa S, Yabe H, Kaneko N, Watanabe E, Gono T, Terai C.
   Intern Med. 2017;56(20):2779-83.

2. Clinical manifestations of Behçet's disease depending on sex and age: results from Japanese nationwide registration.

   Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, Hayashi T, Meguro A, Ishido M, Minegishi K, Yoshimi R, Kirino Y, Kato S, Arimoto J, Ishigatsubo Y, Takeno M, Kurosawa M, Kaneko T, Mizuki N.
   Rheumatology (Oxford). 56(11):1918-1927, 2017

3. Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fc receptors.

   Nishimoto T, Okazaki Y, Numajiri M, and *Kuwana M.
   Int. J. Hematol. 2017; 105(5): 598-605. Epub ahead of print. doi: 10.1007/s12185-016-2172-2.

4. Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and a line blot assay.

   Hamaguchi Y, Kuwana M, and Takehara K.
   Mod. Rheumatol. 2017; 27(3): 551-552. doi: 10.1080/14397595.2016.1213947.

5. A to-do list at diagnosis of systemic sclerosis in case of positive anti-RNA polymerase III antibodies.

   Kuwana M.
   J. Rheumatol. 2017; 44(5): 550-552. doi: 10.3899/jrheum.170037.

6. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting.

   Kuwana M.
   J. Nippon Med. Sch. 2017; 84(2): 56-63.

7. Anti-signal recognition particle antibody in patients without inflammatory myopathy; a survey of 6180 patients with connective tissue diseases.

   Hanaoka H, Kaneko Y, Suzuki S, Takada T, Hirakata M, Takeuchi T, and Kuwana M.
   Scand. J. Rheumatol. Epub ahead of print. doi: 10.3109/03009742.2015.1054876.

8. Tacrolimus in combination with methotrexate and corticosteroid for the treatment of child-onset anti-SRP antibody-positive necrotizing myopathy.

   Kobayashi N, Tozawa Y, Ueko M, Takezaki S, Watanabe S, Iwafuchi H, Yasuda M, Kuwana M, and Ariga T.
   Scand. J. Rheumatol. Epub ahead of print. doi: 10.1080/03009742.2016.1241297.

9. Three cases of interstitial pneumonia with anti-signal recognition particle antibody.

   Togawa R, Tanino Y, Nikaido T, Fukuhara N, Uematsu M, Misa K, Matsuda N, Sugiura Y, Kobayashi H, Hamaguchi Y, Fujimoto M, Kuwana M, and Munakata M.
   Allergol. Int. Epub ahead of print. doi: 10.1016/j.alit.2016.10.009.

10. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a postmarketing surveillance study of 2679 patients in Japan.

    Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, and Koike T.
    Mod. Rheumatol. 2017; 27(5): 755-765. doi: 10.1080/14397595.2016.1265695.

11. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

    Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, and Rubin LJ.
    Ann. Rheum. Dis. Epub ahead of print. doi: 10.1136/annrheumdis-2016-210236.

12. Trans-ethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis.

    Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cernic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelman N, Baron M, Atsumi T, Hassouns P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, and Allanore Y.
    Ann. Rheum. Dis. Epub ahead of print. doi: 10.1136/annrheumdis-2016-210645.

13. Pre-treatment Interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging rheumatoid arthritis patients.

    Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina N, Kuwana M, Jinzaki M, and Takeuchi T.
    Rheumatology. 2017; 56(7): 1089-1094. doi: 10.1093/rheumatology/kex046.

14. Complex pathophysiology of pulmonary hypertension associated with systemic sclerosis: potential unfavorable effects of pulmonary vasodilators.

    Shirai Y, and Kuwana M.
    J. Scleroderma Rel. Dis. 2017; 2(2): 92-99. doi:10.5301/jsrd.5000235.

15. RXRB is a novel MHC-encoded susceptibility gene associated with anti-topoisomerase I antibody-positive systemic sclerosis.

    Oka A, Asano Y, Hasegawa M, Fujimoto M, Ishikawa O, Kuwana M, Kawaguchi Y, Yamamoto T, Takahashi H, Goto D, Endo H, Jinnin M, Mano S, Hosomichi K, Mabuchi T, Takahashi-Ueda M, Nakagawa S, Beck S, Bahram S, Takehara K, Sato S, and Ihn H.
    J. Invest. Dermatol. 2017; 137(9): 1878-1886. doi: 10.1016/j.jid.2017.04.028.

16. HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis.

    Chen Z, Wang Y, Kuwana M, Xu X, Hu W, Feng X, Wang H, Kimura A, and Sun L.
    J. Rheumatol. 2017; 44(9): 1389-1393. doi: 10.3899/jrheum.170165.

17. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities.

    Varga J, Trojanowska M, and *Kuwana M.
    J. Scleroderma Relat. Disord. 2017; 2(3): 137-152. doi: 10.5301/jsrd.5000249.

18. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension.

    Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Abe K, Tsuzino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K, and the Japan PH Registry (JAPHR) Network.
    Circ. J. 2017; 82(1): 275-282. doi: 10.1253/circj.CJ-17-013.

19. On-demand ultrasonography assessment in the most symptomatic joint supports the 8-joint score system for management of rheumatoid arthritis patients.

    Yoshimi R, Takeno M, Toyota Y, Tsuchida N, Sugiyama Y, Kunishita Y, Kishimoto D, Kamiyama R, Minegishi K, Hama M, Kirino Y, Ishigatsubo Y, Ohno S, Ueda A, Nakajima H.
    Mod Rheumatol. 2017, 27(2): 257-265.

20. Thymoma-associated multi-organ autoimmunity: A case of graft-versus-host disease-like erythroderma complicated by Good syndrome successfully treated by thymectomy.

    Fukushima A, Ichimura Y, Obata S, Kinoshita-Ise M, Fujio Y, Takeno M, Konohana I.
    J Dermatol. Epub ahead of print. doi: 10.1111/1346-8138.13777.

21. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.

    Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, and Hoshino T.
    Respir. Invest. 2017; 55(1): 24-32. doi: 10.1016/j.resinv.2016.08.007.

22. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: prospective, multicenter, open-label study.

    Hamaguchi Y, Sumida T, Kawaguchi Y, Ihn H, Tanaka S, Asano Y, Motegi S, Kuwana M, Endo H, and Takehara K.
    J. Dermatol. 2017; 44(1): 13-17. doi: 10.1111/1346-8138.13497.

23. Autoantibody to scaffold attachment factor B (SAFB): a novel connective tissue disease-related autoantibody associated with interstitial lung disease.

    Takeuchi A, Matsushita T, Kaji K, Okamoto Y, Yasui M, Hirata K, Oishi N, Higashi A, Seishima M, Asano T, Fujimoto M, Kuwana M, Takehara K, and Hamaguchi Y.
    J. Autoimmun. 2017; 76(1): 101-107. doi: 10.1016/j.jaut.2016.09.006.

24. Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease.

    Naniwa T, Tamechika S, Okazaki Y, Maeda S, and Kuwana M.
    MR Case Rep. 2017; 1(1): 3-8. doi: 10.1080/24725625.2016.1253650.

25. Surgery, westernized dietary habits and other risk factors for mixed connective tissue disease in a Japanese population: comparison with systemic lupus erythematosus and systemic sclerosis.

    Washio M, Fukaya S, Kuwana M, Tanaka S, Matsushita M, Fujii T, Kawaguchi Y, Kawahata K, Toyoshima Y, Mori M, and Yoshida S.
    Int. Med. J. 2017; 24(1): 12-17.

26. Use and standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

    Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger TA, Jr, Merkel PA, Pope JE, Seibold JR, Steen VD, Denton CP, on behalf of the Scleroderma Clinical Trials Consortium and the World Scleroderma Foundation.
    J. Scleroderma Rel. Dis. 2017; 2(1): 11-18.

27. Sarcoplasmic MxA expression -a marker highly diagnostic of dermatomyositis.

    Uruha A, ishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, and Nishino I.
    Neurology. 2017; 88(5): 493-500. doi: 10.1212/WNL.0000000000003568.

28. T cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.

    Rubic-Schneider T, Kuwana M, Christen B, Assenmacher M, Hainzl O, Zimmermann F, Fischer R, Koppenburg V, Chibout SD, Wright TM, Seidl A, and Kammüller M.
    Blood Adv. 2017; 1(6): 367-379. doi 10.1182/bloodadvances.2016001842.

29. Anti-MDA5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.

    Matsushita T, Mizukami K, Kano M, Yagi M, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, and Takehara K.
    Br. J. Dermatol. 2017; 176(2): 395-402. doi: 10.1111/bjd.14882.

30. Anti-MDA5 autoantibody: expanding the clinical spectrum in North American dermatomyositis patients.

    Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, and Aggarwal R.
    J. Rheumatol. 2017; 44(3): 319-325. doi: 10.3899/jrheum.160682.

31. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody-associated vasculitis.

    Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, Terai C.
    BMC Immunol. 2017;18(1):53.

2016年

1. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies.

   Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, and *Kuwana M.
   PLoS One. 2016; 11(4): e0154285. doi: 10.1371/journal.pone.0154285.

2. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis.

   Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, and Aggarwal R.
   Arthritis Care Res. 2016; 68(5): 689-694. doi: 10.1002/acr.22728.

3. Association of psoriasis with Hashimoto’s thyroiditis, Sjӧgren syndrome and dermatomyositis.

   Akiyama M, Ueno T, Kanzaki A, Kuwana M, Nagao M, and Saeki H.
   J. Dermatol. 2016; 43(6): 711-712. doi: 10.1111/1346-8138.13265

4. What do we learn from immunomodulation in patients with immune thrombocytopenia?

   Kuwana M.
   Semin. Hematol. 2016; 53: S27-S30. doi: 10.1053/j.seminhematol.2016.04.009.

5. Choosing the right biomarkers to predict ILD in myositis.

   Gono T, and *Kuwana M.
   Nat. Rev. Rheumatol. 2016; 12(9): 504-506. doi:10.1038/nrrheum.2016.120

6. Gottron’s papules and Gottron’s sign with ulceration: A distinctive cutaneous feature in a subset of DM/CADM patients.

   Cao H, Xia Q, Pan M, Zhao X, Li X, Shi R, Ding X, Kuwana M, and Zheng J.
   J. Rheumatol. 2016; 43(9): 1735-1742. doi: 10.3899/jrheum.160024.

7. Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation.

   Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, and Takeuchi T.
   Mod. Rheumatol. 2016; 26(5): 790-793. doi: 10.3109/14397595.2014.919707.

8. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease.

   Kuwana M, Shirai Y, and Takeuchi T.
   J. Rheumatol. 2016; 43(10): 1825-1831.

9. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 and anti-Mi-2 autoantibodies in dermatomyositis.

   Fujimoto M, Murakami A, Kurei S, Okiyama N, Kawakami A, Mishima M, Sato S, Seishima M, Suda T, Mimori T, Takehara K, and Kuwana M.
   J. Dermatol. Sci. 2016; 84(3): 272-281. doi: 10.1016/j.jdermsci.2016.09.013.

10. Recent updates in experimental protocols for endothelial cells.

    Kahaleh B, Guiducci S, and Kuwana M.
    J. Scleroderma Rel. Dis. 2016; 1(3): 257-265.

11. Clinical manifestations and myositis-specific autoantibodies associated with physical dysfunction after treatment in patients with polymyositis and dermatomyositis: An observational study of physical dysfunction with myosits in Japan.

    Kawasumi H, Gono T, Kawaguchi Y, Kuwana M, Kaneko H, Katsumata Y, Kataoka S, Hanaoka M, and Yamanaka H.
    BioMed Res. Int. 2016; 2016: 9163201. doi: 10.1155/2016/9163201.

12. Introducing the Journal of Scleroderma and Related Disorders, a challenge for the future of our community.

    Kuwana M and Matucci Cerinic M.
    J. Scleroderma Rel. Dis. 2016; 1(1): 1.

13. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum.

    Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, and Sun L.
    Clin. Rheumatol. 2016; 35(2): 489-493. doi: 10.1007/s10067-015-3001-3.

14. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis.

    Hanaoka H, Ota Y, Takeuchi T, and Kuwana M.
    Clin. Rheumatol. 2016; 35(2): 495-500. doi: 10.1007/s10067-015-3162-0.

15. Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia.

    Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, Ueda A, Tateishi U, Ishigatsubo Y.
    Mod Rheumatol. 2016, 26(1): 121-127. doi: 10.3109/14397595.2015.1054099. PubMed PMID:25995034.

16. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis.

    Watanabe T, Takase-Minegishi K, Ihata A, Kunishita Y, Kishimoto D, Kamiyama R, Hama M, Yoshimi R, Kirino Y, Asami Y, Suda A, Ohno S, Tateishi U, Ueda A, Takeno M, Ishigatsubo Y.
    Mod Rheumatol. 2016, 26(2): 180-187.

17. Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet's disease: a retrospective observational study.

    Kirino Y, Ideguchi H, Takeno M, Suda A, Higashitani K, Kunishita Y, Takase-Minegishi K, Tamura M, Watanabe T, Asami Y, Uehara T, Yoshimi R, Yamazaki T, Sekiguchi A, Ihata A, Ohno S, Ueda A, Igarashi T, Nagaoka S, Ishigatsubo Y, Nakajima H.
    Arthritis Res Ther. 2016, 18(1): 217.

18. Clinical value of capsule endoscopy for detecting small bowel lesions in patients with intestinal Behçet's disease.

    Arimoto J, Endo H, Kato T, Umezawa S, Fuyuki A, Uchiyama S, Higurashi T,Ohkubo H, Nonaka T, Takeno M, Ishigatsubo Y, Sakai E, Matsuhashi N, Nakajima A.
    Dig Endosc. 2016, 28(2): 179-185.

19. M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo.

    Atanelishvili I, Shirai Y, Akter T, Buckner T, Noguchi A, Silver RM, Bogatkevich GS.
    Transl Res. 2016 Apr;170:99-111. doi: 10.1016/j.trsl.2015.12.009.

20. D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts.

    Atanelishvili I, Shirai Y, Akter T, Noguchi A, Ash KT, Misra S, Ghatak S, Silver RM, Bogatkevich GS.
    PLoS One. 2016 Sep 1;11(9):e0162357. doi: 10.1371/journal.pone.0162357.

2015年

1. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behçet’s disease.

   Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y.
   J. Neurol. Sci. 2015; 349(1-2): 143-148. doi: 10.1016/j.jns.2015.01.005.

2. β2-glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantigens in multiple MHC class II haplotypes.

   Salem D, Subang R, Okazaki Y, Laplante P, Levine JS, Kuwana M, and Rauch J.
   J. Biol. Chem. 2015; 290(9): 5543-5555. doi: 10.1074/jbc.M114.619817.

3. Clinical and immunological predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III antibodies.

   Hamaguchi Y, Kodera M, Matsushita T, Usuda T, Kuwana M, Takehara K, and Fujimoto M.
   Arthritis Rheumatol. 2015; 67(4): 1045-1052. doi: 10.1002/art.38994.

4. S Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.

   Kimura M, Tamura Y, Takei M, Yamamoto T, One T, Kuwana M, Fukuda K, and Satoh T.
   PLoS One. 2015; 10(4): e0121894. doi: 10.1371/journal.pone.0121894.

5. Reply: Assessment of elevated pentraxin 3 in systemic sclerosis (letter).

   Shirai Y and Kuwana M.
   Arthritis Rheumatol. 2015; 67(5):1409-1410. doi: 10.1002/art.39032.

6. Cinical and laboratory features of fetal rapidly progressive interstitial lung diseases associated with juvenile dermatomyositis.

   Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Yokota S, Koike K, and Ariga T.
   Rheumatology. 2015; 54(5): 784-791. doi: 10.1093/rheumatology/keu385.

7. An unusual association between focal segmental sclerosis and lupus nephritis: a distinctive concept from lupus podocytopathy?

   Hanaoka H, Hashiguchi A, Konishi K, Kuwana M, and Takeuchi T.
   CEN Case Reports. 2015; 4(1): 70-75.

8. Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.

   Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, and Takeuchi T.
   Intern. Med. 2015; 54(9): 1131-4. doi: 10.2169/internalmedicine.54.4188.

9. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.

   Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, and Fukuda K.
   BMC Pulm. Med. 2015; 15: 62. doi: 10.1186/s12890-015-0037-8.

10. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients.

    Suzuki S, Nishiikawa A, Kuwana M, Nishimura H, Watanabe Y, Hayashi YK, Suzuki N, and Nishino I.
    Orphanet J. Rare Dis. 2015;10(1): 61. doi: 10.1186/s13023-015-0277-y.

11. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis.

    Hamada-Ode K, Taniguchi Y, Kimata T, Kawaguchi Y, Shimamura Y, Kuwana M, Fujimoto S, and Terada Y.
    Eur. J. Rheumatol. 2015; 2: 83-85. doi: 10.5152/eurjrheum.2015.0076.

12. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.

    Tamura Y, Kimura M, Takei M, Ono T, Kuwana M, Satoh T, Fukuda K, and Humbert M.
    Eur. Respir. J. 2015; 46(1): 283-286. doi: 10.1183/09031936.00044915.

13. Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap.

    Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Teramoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, and Matsuda F.
    Arthritis Rheumatol. 2015; 67(8): 2226-2232. doi: 10.1002/art.39157.

14. Aggregation of rare/low frequency variants of the mitochondria respiratory chain-related proteins in rheumatoid arthritis patients.

    Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Oka A, Shiina T, Ishii N, Inoko H, and Inoue I.
    J. Hum. Genet. 2015;60(8): 449-454. doi: 10.1038/jhg.2015.50.

15. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis.

    Chen Z, Hu W, Wang Y, Guo Z, Sun L, and *Kuwana M.
    Clin. Rheumatol. 2015; 34(9): 1627-1631. doi: 10.1007/s10067-015-2935-9.

16. Reply: Clinical and immunological predictors of scleroderma renal crisis for Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies (letter).

    Hamaguchi Y, Kuwana M, and Fujimoto M.
    Arthritis Rheumatol. 2015; 67(9): 2548. doi: 10.1002/art.39201.

17. Early achievement of complete renal response predicts long-term good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV.

    Hanaoka H, Kaneko Y, Kuwana M, and Takeuchi T.
    Mod. Rheumatol. 2015; 25(5): 714-718. doi: 10.3109/14397595.2014.1003172.

18. Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting.

    Sato S, and Kuwana M.
    Int. J. Clin. Rheumatol. 2015; 10(4): 257-271. doi: 10.2217/ijr.15.27.

19. Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes.

    Hanaoka H, Kuwana M, and Takeuchi T.
    Int. J. Rheum Dis. 2015; 18(7): 768-775. doi: 10.1111/1756-185X.12682

20. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.

    Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, and Sasayama S.
    Heart Vessels. 2015; 30(6): 798-804.

21. Tocilizumab is effective for polymyalgia rheumatica: experience in 13 intractable cases.

    Izumi K, Kuda K, Ushikubo M, Kuwana M, Takeuchi T, and Ohshima H.
    RMD Open. 2015; 1: e000162. doi:10.1136/rmdopen-2015-000162

22. Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus.

    Hanaoka H, Okazaki Y, Hashiguchi A, Yasuoka H, Takeuchi T, and Kuwana M.
    Clin. Exp. Rheumatol. 2015; 33(6): 863-870.

2014年

1. Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia.

   *Kuwana M, Okazaki Y, and Ikeda Y.
   PLoS One. 2014; 9(1): e86943.

2. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study.

   Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, and Takehara K.
   PLoS One. 2014; 9(2): e88150.

3. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies.

   Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, and Suzuki N.
   Eur. J. Neurol. 2014; 21(2): 223-230.

4. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement.

   Kaji K, Noreen F, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucus M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, and *Kuwana M.
   Arthritis Care Res. 2014; 66(4): 575-584.

5. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.

   Saketkoo LA, Mittoo S, Frankel S, Lesage D, Sarver C, Phillips K, Strand V, Matteson EL, OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group, and Delphi Process Collaborators.
   J. Rheumatol. 2014; 41(4): 792-798.

6. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

   Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR and Dephi co-authors.
   Thorax. 2014; 69(5): 436-444.

7. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.

   Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, and Kuwana M.
   Clin. Exp. Rheumatol. 2014; 32(2): 211-217.

8. Impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis.

   *Kuwana M, and Okazaki Y.
   Arthritis Rheumatol. 2014; 66(5): 1300-1305.

9. IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment.

   Shirai Y, Tamura Y, Yasuoka H, Satoh T, and *Kuwana M.
   Eur. Respir. J. 2014; 43(5): 1516-1519.

10. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional disorder.

    Kaneko Y, Kuwana M, Kondo H, and Takeuchi T.
    J. Rheumatol. 2014; 41(6): 1061-1066.

11. Distinct arthropathies in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients.

    Kaneko Y, Hanaoka H, Hirakata M, Takeuchi T, and Kuwana M.
    Rheumatology. 2014; 53(6): 1120-1124.

12. Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus.

    Washio M, Fujii T, Kuwana M, Kawaguchi Y, Mimori A, Horiuchi T, Tada Y, Takahashi H, Mimori T, and Japan MCTD study group.
    Mod. Rheumatol. 2014; 24(5): 788-792.

13. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopthies.

    Suzuki S, Yonekawa T, Kuwana M, Hayashi YK, Okazaki Y, Kawaguchi Y, Suzuki N, and Nishino I.
    J. Neuroimmunol. 2014; 274(1-2): 202-208.

14. Recurrent right atrial thrombosis due to Behçet’s disease.

    Kuno T, Tamura Y, Kimura K, Ono T, Murata M, Kuwana M, Satoh T, and Fukuda K.
    Can. J. Cardiol. 2014; 30(10): 1250.e1-3.

15. Fatal case of clinically amyopathic dermatomyositis: cotton-wool spots as a sign of an aggressive subtype of dermatomyositis.

    Ito A, Nakamura Y, Saito K, Sho Y, Ishikawa K, Shimada H, Hatano Y, Okamoto O, Haranaka M, Ishii K, Nakamuro T, Kimoto K, Kuwana M, Hamaguchi Y, and Fujiwara S.
    J. Dermatol. 2014; 41(10): 943-944.

16. A rare association of Fabry’s disease and granulomatosis with polyangiitis: a potential pathogenic link.

    Hanaoka H, Hashiguchi A, Konishi K, Ishii T, and Kuwana M.
    BMC Nephrol. 2014; 15(1): 157.

17. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia.

    Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, and *Kuwana M.
    Int. J. Hematol. 2014;100(4): 341-344.

18. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis specific autoantibodies in dermatomyositis patients.

    Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, and Song YW.
    Mod. Rheumatol. 2014; 26(6): 945-948.

19. Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease.

    Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y.
    Mod. Rheumatol. 2014; 24(6): 961-965.

20. Cytokine profiles in polymyositis and dermatomyositis complicated with rapidly progressive or chronic interstitial lung disease.

    Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, and Yamanaka H.
    Rheumatology. 2014; 53(12): 2196-2203.

21. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52.

    Izumi K , Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T.
    Mod. Rheumatol. In press.

22. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.

    Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, and Kawakami A.
    Mod. Rheumatol. In press.

23. Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation.

    Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, and Takeuchi T.
    Mod. Rheumatol. In press.

24. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.

    Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, and Sasayama S.
    Heart Vessels. In press.

25. Cinical and laboratory features of fetal rapidly progressive interstitial lung diseases associated with juvenile dermatomyositis.

    Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Yokota S, Koike K, and Ariga T.
    Rheumatology. In press.

26. An unusual association between focal segmental sclerosis and lupus nephritis: a distinctive concept from lupus podocytopathy?

    Hanaoka H, Hashiguchi A, Konishi K, Kuwana M, and Takeuchi T.
    CEN Case Reports. In press.

27. Elevated pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis.

    Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, and *Kuwana M.
    Arthritis Rheumatol. In press.

    Supplementary data(PDF:1.67MB, English)

28. Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and a literature review.

    Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, and Takeuchi T.
    Intern. Med. In press.

29. Clinical and immunological predictors of scleroderma renal crisis for Japanese systemic sclerosis patients with anti-RNA polymerase III antibody.

    Hamaguchi Y, Kodera M, Matsushita T, Usuda T, Kuwana M, Takehara K, and Fujimoto M.
    Arthritis Rheumatol. In press.

総説- Reviews -

1. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms.

   *Kuwana M.
   World J Gastroenterol. 2014; 20(3): 714-723.

2. How to detect early stage rheumatoid arthritis (RA) in persons undergoing ningen dock (Health evaluation and promotion).

   Kaburaki J, and Kuwana M.
   Ningen Dock Int. 2014; 1(1): 24-33.

3. Dysregulated negative immune regulators in immune thrombocytopenia.

   *Kuwana M.
   ISBT Sci. Ser. In press.

特別講演- Invited lectures -

1. Potential roles of circulating endothelial progenitor cells and monocytes in the pathogenesis of systemic sclerosis.

   Kuwana M
   International Network of Scleroderma Clinical Care and Research (Shanghai). 2014. 3.

2. Clinical associations of autoantibodies in SSc.

   Kuwana M
   The 4th Symposium of International Network of Scleroderma Clinical Care and Research (Shanghai). 2014. 3.

3. Current topics of Behçet’s disease in Japan.

   Takeno M
   16th Annual Meeting of the Korean Society for Behçet’s Disease (Seoul). 2015.10.

一般演題- Abstructs -

1. Complex pathophysiology of pulmonary hypertension associated with systemic sclerosis: merits and demerits of aggressive treatment with pulmonary vasodilators.

   Kuwana M
   3rd Systemic Sclerosis World Congress (Rome). 2014. 2.

2. Excessive fibrosis and pulmonary vascular remodeling in Fra-1 transgenic mice.

   Yasuoka H, Okazaki Y, Tam A, Tamura Y, Takada I, Matsuo K, Takeuchi T, Kuwana M
   3rd Systemic Sclerosis World Congress (Rome). 2014. 2.

3. Validation of preliminary algorithm for differential diagnosis of thrombocytopenia in patients with systemic lupus erythematosus.

   Kuwana M, Okazaki Y, Hanaoka H, Takeuchi T
   The European League Against Rheumatism 2014 (Paris). 2014. 6.

4. Elevated Pentraxin 3 in Patients with Systemic Sclerosis: Associations with Vascular Manifestations and Defective Vasculogenesis.

   Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, and Kuwana M
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

5. Takayasu Arteritis and Ulcerative Colitis-High Concurrence Raito and Genetic Overlap.

   Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, and Matsuda F
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

6. Association of Hand MRI Findings with the Level of Plasma Cytokines in Patients with Newly Diagnosed Rheumatoid Arthritis.

   Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina N, Kuwana M, Jinzaki M and Takeuchi T
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

7. A New Multianalyte Assay for Detection of Dermatomyositis-Specific Autoantibodies Undetectable By Commercially Available Immunoassays.

   Kuwana M, Okazaki Y and Takeuchi T
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

8. Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyosits: Utility and Crossreactivity.

   Fujimoto M, Murakami A, Kurei S, Kuwajima A, Fujisawa Y, Kawakami A, Mishima M, Sato S, Seishima M, Suda T, Mimori T, Takehara K and Kuwana M
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

9. A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody.

   Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M and Kuwana M
   The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

10. Anti-MDA5 is Associated with Rapidly-Progresstive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis.

    Moghadam-K S, Oddis C.V, Sato S, Kuwana M and Aggarwal R
    The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

11. Up-Regulated Expression of CXCR4 on Circulating B Cells in Patients with Systemic Lupus Erythematosus.

    Hanaoka H, Okazaki Y, Hashiguchi A, Yasuoka H, Takeuchi T and Kuwana M
    The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

12. Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease.

    Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M and Ishigatsubo Y
    The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

13. Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis.

    Shirai Y, Atanelishvili I, Akter T, Silver RM and Bogatkevich GS
    The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11

14. IQGAP1 Enhances Contractility of Scleroderma Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fibrosis.

    Akter T, Atanelishvili I, Shirai Y, Nelson SP, Garcia-Martos A, Morinelli TA, Silver RM and Bogatkevich GS
    The 78th Annual Scientific Meeting of American College of Rheumatology (Boston). 2014. 11